{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:11:09Z","timestamp":1778220669331,"version":"3.51.4"},"posted":{"date-parts":[[2026,4,29]]},"group-title":"Immunology","reference-count":59,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The persistence of latent HIV-1 reservoirs remains the primary barrier to a cure. Shock and kill strategies aim to reactivate these reservoirs and eliminate them via effector cells, such as Natural Killer (NK) cells. However, chronic infection leaves NK cells exhausted. In this study, we investigated the interplay between cytokine-mediated NK cell activation and antibody-dependent cellular cytotoxicity (ADCC) across diverse HIV-1 subtypes. We demonstrated that while cytokine stimulation enhanced natural cytotoxicity, it simultaneously induces shedding of the Fc receptor CD16 via the metalloproteinase enzyme ADAM17. However, restoring CD16 expression through ADAM17 inhibition (TAPI-1) did not improve ADCC, suggesting that CD16 surface levels in NK cells is not the only limiting factor. On the other hand, Fc-engineered broadly neutralizing antibodies (bNAbs) with increased CD16 affinity, in particular LPLIL and GASDALIE, significantly enhance ADCC across the six different HIV-1 subtypes, regardless of NK cells activation, CD16 downregulation or limited surface Envelope expression in CD4T cells. These findings suggest that enhancing receptor affinity of bNAbs can bypass viral immune evasion and NK cell exhaustion, supporting their potential incorporation into HIV cure strategies.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>\n                    Eradicating latent HIV reservoirs remains a global health priority, as it would liberate millions of people living with HIV (PLWH) from the economic and physiological burdens of lifelong antiretroviral therapy (ART). By utilizing a primary human cell model that resembles\n                    <jats:italic>in vivo<\/jats:italic>\n                    conditions across diverse viral strains, we identified that simply preventing CD16 receptor shedding from NK cells is insufficient to improve HIV-1 clearance. Instead, we demonstrated that enhancing the binding of antibodies to the CD16 receptor enables NK cells to overcome viral immune evasion and the loss of CD16 expression. This allows for potent elimination of infected cells through antibody-dependent cellular cytotoxicity (ADCC). These findings provide a clear strategy for designing more effective \u201ckill\u201d components in future therapeutic strategies.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.04.27.721006","type":"posted-content","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:46:18Z","timestamp":1777531578000},"source":"Crossref","is-referenced-by-count":0,"title":["HIV broadly neutralizing antibodies with enhanced Fc-CD16 affinity increase NK cell ADCC even with limited envelope binding"],"prefix":"10.64898","author":[{"given":"Claudia","family":"Melo","sequence":"first","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carissa S","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse K","family":"McMahon","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S","family":"Lochner","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca M","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-2160","authenticated-orcid":false,"given":"Alberto","family":"Bosque","sequence":"additional","affiliation":[{"name":"Department of, Microbiology, Immunology & Tropical Medicine, Washington, DC, USA., The George Washington University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026050722185544000_2026.04.27.721006v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1916753"},{"key":"2026050722185544000_2026.04.27.721006v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2016.01.006"},{"key":"2026050722185544000_2026.04.27.721006v1.3","unstructured":"Waymack JR , Sundareshan V . Acquired Immune Deficiency Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"2026050722185544000_2026.04.27.721006v1.4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02517"},{"key":"2026050722185544000_2026.04.27.721006v1.5","doi-asserted-by":"crossref","unstructured":"Thomas J , Ruggiero A , Paxton WA , Pollakis G . Measuring the Success of HIV-1 Cure Strategies. Front Cell Infect Microbiol. 2020;10:134.","DOI":"10.3389\/fcimb.2020.00134"},{"key":"2026050722185544000_2026.04.27.721006v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3132"},{"key":"2026050722185544000_2026.04.27.721006v1.7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007161"},{"key":"2026050722185544000_2026.04.27.721006v1.8","doi-asserted-by":"publisher","DOI":"10.1159\/000445852"},{"key":"2026050722185544000_2026.04.27.721006v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/487439a"},{"key":"2026050722185544000_2026.04.27.721006v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.12.004"},{"key":"2026050722185544000_2026.04.27.721006v1.11","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000688"},{"key":"2026050722185544000_2026.04.27.721006v1.12","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000286"},{"key":"2026050722185544000_2026.04.27.721006v1.13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02290"},{"key":"2026050722185544000_2026.04.27.721006v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27647-0"},{"key":"2026050722185544000_2026.04.27.721006v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115"},{"key":"2026050722185544000_2026.04.27.721006v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482"},{"key":"2026050722185544000_2026.04.27.721006v1.17","first-page":"6437057","article-title":"Research Progress on NK Cell Receptors and Their Signaling Pathways","volume":"2020","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2026050722185544000_2026.04.27.721006v1.18","doi-asserted-by":"crossref","unstructured":"Gotthardt D , Sexl V . STATs in NK-Cells: The Good, the Bad, and the Ugly. Front Immunol. 2016;7:694.","DOI":"10.3389\/fimmu.2016.00694"},{"issue":"2","key":"2026050722185544000_2026.04.27.721006v1.19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11904-016-0310-3","article-title":"NK Cells in HIV Disease","volume":"13","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026050722185544000_2026.04.27.721006v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00732-1"},{"key":"2026050722185544000_2026.04.27.721006v1.21","doi-asserted-by":"crossref","unstructured":"Awan SF , Pegu A , Strom L , Carter CA , Hendel CS , Holman LA , et al. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS. JCI Insight. 2024;9(7).","DOI":"10.1172\/jci.insight.175375"},{"key":"2026050722185544000_2026.04.27.721006v1.22","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiac007"},{"key":"2026050722185544000_2026.04.27.721006v1.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438"},{"issue":"5","key":"2026050722185544000_2026.04.27.721006v1.24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026050722185544000_2026.04.27.721006v1.25","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000600"},{"key":"2026050722185544000_2026.04.27.721006v1.26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.15698\/mic2024.07.826","article-title":"Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention","volume":"11","year":"2024","journal-title":"Microb Cell"},{"key":"2026050722185544000_2026.04.27.721006v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.02.010"},{"key":"2026050722185544000_2026.04.27.721006v1.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1321507111"},{"key":"2026050722185544000_2026.04.27.721006v1.29","doi-asserted-by":"crossref","unstructured":"Matson AW , Hullsiek RH , Dixon KJ , Wang S , Lindstedt AJ , Friess RR , et al. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells. bioRxiv. 2024.","DOI":"10.1101\/2024.05.09.593347"},{"key":"2026050722185544000_2026.04.27.721006v1.30","doi-asserted-by":"crossref","unstructured":"Mishra HK , Dixon KJ , Pore N , Felices M , Miller JS , Walcheck B . Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation. Front Immunol. 2021;12:711621.","DOI":"10.3389\/fimmu.2021.711621"},{"key":"2026050722185544000_2026.04.27.721006v1.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425397"},{"issue":"9","key":"2026050722185544000_2026.04.27.721006v1.32","doi-asserted-by":"crossref","first-page":"e1011629","DOI":"10.1371\/journal.ppat.1011629","article-title":"Multiplex interrogation of the NK cell signalome reveals global downregulation of CD16 signaling during lentivirus infection through an IL-18\/ADAM17-dependent mechanism","volume":"19","year":"2023","journal-title":"PLoS Pathog"},{"key":"2026050722185544000_2026.04.27.721006v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.2MR1218-501R"},{"key":"2026050722185544000_2026.04.27.721006v1.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056309"},{"key":"2026050722185544000_2026.04.27.721006v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.023"},{"key":"2026050722185544000_2026.04.27.721006v1.36","doi-asserted-by":"crossref","unstructured":"Schriek AI , Falck D , Wuhrer M , Kootstra NA , van Gils MJ , de Taeye SW . Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions. Antiviral Res. 2024;231:106015.","DOI":"10.1016\/j.antiviral.2024.106015"},{"key":"2026050722185544000_2026.04.27.721006v1.37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02590"},{"key":"2026050722185544000_2026.04.27.721006v1.38","doi-asserted-by":"publisher","DOI":"10.2741\/3051"},{"key":"2026050722185544000_2026.04.27.721006v1.39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120944"},{"key":"2026050722185544000_2026.04.27.721006v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.006"},{"key":"2026050722185544000_2026.04.27.721006v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.06.025"},{"issue":"15","key":"2026050722185544000_2026.04.27.721006v1.42","doi-asserted-by":"crossref","first-page":"e0037222","DOI":"10.1128\/jvi.00372-22","article-title":"The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation","volume":"96","year":"2022","journal-title":"J Virol"},{"key":"2026050722185544000_2026.04.27.721006v1.43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0696"},{"key":"2026050722185544000_2026.04.27.721006v1.44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009483200"},{"key":"2026050722185544000_2026.04.27.721006v1.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"key":"2026050722185544000_2026.04.27.721006v1.46","doi-asserted-by":"crossref","unstructured":"Ren Y , Korom M , Ward AR , Truong R , Chan D , Huang SH , et al. Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV. J Virol. 2020;95(2).","DOI":"10.1128\/JVI.01808-20"},{"key":"2026050722185544000_2026.04.27.721006v1.47","doi-asserted-by":"crossref","unstructured":"Garrido C , Abad-Fernandez M , Tuyishime M , Pollara JJ , Ferrari G , Soriano-Sarabia N , et al. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J Virol. 2018;92(12).","DOI":"10.1128\/JVI.00235-18"},{"key":"2026050722185544000_2026.04.27.721006v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2016.02.001"},{"issue":"1","key":"2026050722185544000_2026.04.27.721006v1.49","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1038\/s41467-024-51848-y","article-title":"Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fc\u03b3 receptors during acute SHIVAD8-EO infection","volume":"15","year":"2024","journal-title":"Nat Commun"},{"key":"2026050722185544000_2026.04.27.721006v1.50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122466"},{"key":"2026050722185544000_2026.04.27.721006v1.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01651-9"},{"key":"2026050722185544000_2026.04.27.721006v1.52","doi-asserted-by":"crossref","unstructured":"Howard JN , Bosque A . IL-15 and N-803 for HIV Cure Approaches. Viruses. 2023;15(9).","DOI":"10.3390\/v15091912"},{"key":"2026050722185544000_2026.04.27.721006v1.53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.11.4964-4972.2001"},{"issue":"9","key":"2026050722185544000_2026.04.27.721006v1.54","doi-asserted-by":"crossref","first-page":"e0009622","DOI":"10.1128\/jvi.00096-22","article-title":"Pharmacological Targeting of Sphingosine Kinases Impedes HIV-1 Infection of CD4 T Cells through SAMHD1 Modulation","volume":"96","year":"2022","journal-title":"J Virol"},{"key":"2026050722185544000_2026.04.27.721006v1.55","doi-asserted-by":"crossref","unstructured":"Sarabia I , Huang SH , Ward AR , Jones RB , Bosque A . The Intact Non-Inducible Latent HIV-1 Reservoir is Established In an In Vitro Primary T(CM) Cell Model of Latency. J Virol. 2021;95(7).","DOI":"10.1128\/JVI.01297-20"},{"key":"2026050722185544000_2026.04.27.721006v1.56","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1896-1905.2002"},{"key":"2026050722185544000_2026.04.27.721006v1.57","doi-asserted-by":"crossref","unstructured":"Wilson A , Shakhtour L , Ward A , Ren Y , Recarey M , Stevenson E , et al. Characterizing the Relationship Between Neutralization Sensitivity and env Gene Diversity During ART Suppression. Front Immunol. 2021;12:710327.","DOI":"10.3389\/fimmu.2021.710327"},{"key":"2026050722185544000_2026.04.27.721006v1.58","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-170-3_26"},{"key":"2026050722185544000_2026.04.27.721006v1.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111624"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.04.27.721006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:19:09Z","timestamp":1778217549000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.04.27.721006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":59,"URL":"https:\/\/doi.org\/10.64898\/2026.04.27.721006","relation":{},"subject":[],"published":{"date-parts":[[2026,4,29]]},"subtype":"preprint"}}